Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003961:Dianhydrogalactitol / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013402:Sugar Alcohols / Q000008:administration & dosage*; D013921:Thrombocytopenia / Q000139:chemically induced
D013402:Sugar Alcohols; D003961:Dianhydrogalactitol; D004317:Doxorubicin; D002945:Cisplatin